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	 What	is	the	best	beta-blocker	
for	systolic	heart	failure?	
	 Three beta-blockers—carve-
 dilol, metoprolol succinate, 
and bisoprolol—reduce	mortality	equally	
(by	 about	 30%	 over	 one	 year)	 in	 patients	
with	 Class	 III	 or	 IV	 systolic	 heart	 failure.	
Insufficient	 evidence	 exists	 comparing	
equipotent	 doses	 of	 these	 medications	
head-to-head	to	recommend	any	one	over	
the	 others	 (strength	 of	 recommendation	
[SOR]:	A,	systematic	review/meta-analysis).
evidence summary 
A	 2013	 network	 meta-analysis	 compared	
beta-blockers	 with	 placebo	 or	 standard	
treatment	by	analyzing	21	randomized	trials	
with	a	 total	of	23,122	patients.1	 Investigators	
found	 that	 beta-blockers	 as	 a	 class	 signifi-
cantly	 reduced	 mortality	 after	 a	 median	 of	
12	months	(odds	ratio=0.71,	95%	confidence	
interval	 [CI],	 0.64-0.80;	 number	 needed	 to	
treat	[NNT]=23).		
They	 also	 compared	 atenolol,	 bisopro-
lol,	 bucindolol,	 carvedilol,	 metoprolol,	 and	
nebivolol	with	each	other	and	found	no	sig-
nificant	 difference	 in	 risk	 of	 death,	 sudden	
cardiac	 death,	 death	 resulting	 from	 pump	
failure,	or	tolerability.	
three drugs are more effective  
and tolerable than others 
A	2013	 stratified	 subset	meta-analysis	used	
data	from	landmark	randomized	controlled	
trials	 (RCTs)	 that	 evaluated	 beta-blockers	
vs	 placebo	 in	 patients	 with	 systolic	 heart	
failure	 to	 compare	 metoprolol	 succinate	
(MERIT-HF)	 vs	 placebo	 with	 bisoprolol	
(CIBIS-II),	 carvedilol	 (COPERNICUS),	 and	
nebivolol	(SENIORS-SHF)	vs	placebo	(tABLe).2	
Three	 of	 the	 drugs—bisoprolol,	 carve-
dilol,	 and	 metoprolol	 succinate—showed	
similar	 reductions	 relative	 to	placebo	 in	all-
cause	mortality,	hospitalization	for	heart	fail-
ure,	and	tolerability.	Investigators	concluded	
that	 the	 3	 drugs	 have	 comparable	 efficacy	
and	tolerability,	whereas	nebivolol	is	less	ef-
fective	and	tolerable.	
Carvedilol vs beta-1-selective  
beta-blockers
Another	 2013	meta-analysis	 of	 8	 RCTs	 with	
4563	adult	patients	18	years	or	older	with	sys-
tolic	 heart	 failure	 compared	 carvedilol	 with	
the	 beta-1-selective	 beta-blockers	 atenolol,	
bisoprolol,	nebivolol,	and	metoprolol.3	Inves-
tigators	found	that	carvedilol	significantly	re-
duced	all-cause	mortality	(relative	risk=0.85;	
95%	CI,	 0.78-0.93;	 NNT=23)	 compared	with	
beta-1-selective	beta-blockers.	
However,	 4	 trials	 (including	 COMET,	
N=3029)	 compared	 carvedilol	 with	 short-
acting	metoprolol	 tartrate,	 which	may	 have	
skewed	 results	 in	 favor	 of	 carvedilol.	More-
over,	2	trials	comparing	carvedilol	with	biso-
prolol	and	2	trials	comparing	carvedilol	with	
nebivolol	 found	 no	 significant	 difference	 in	
all-cause	mortality.3
Recommendations 
The	 2010	 Heart	 Failure	 Society	 of	 Ameri-
ca	 Comprehensive	 Heart	 Failure	 Practice	
Guideline	notes	 that	 the	marked	beneficial	
effects	 of	 beta	 blockade	 with	 carvedilol,	
bisoprolol,	 and	 controlled-	 or	 extended-
release	 metoprolol	 have	 been	 well-dem-
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failure.
references
onstrated	 in	 large-scale	 clinical	 trials	 of	
symptomatic	 patients	 with	 Class	 II	 to	 IV	
heart	 failure	 and	 reduced	 left	 ventricular	
ejection	fraction.4
The	 2013	 American	 College	 of	 Cardiol-
ogy	 Foundation/American	 Heart	 Associa-
tion	heart	failure	guideline	recommends	the	
use	 of	 one	 of	 the	 3	 beta-blockers	 proven	 to	
reduce	 mortality	 (bisoprolol,	 carvedilol,	 or	
sustained-release	 metoprolol	 succinate)	 for	
all	 patients	 with	 current	 or	 previous	 symp-
toms	 of	 heart	 failure	 with	 reduced	 ejection	
fraction,	 unless	 contraindicated,	 to	 reduce	
morbidity	and	mortality.5				 													JFP
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tABLe
How	metoprolol	succinate	vs	placebo	compares		
with	other	beta-blockers	vs	placebo2
comparison randomized controlled trials rrr*
Bisoprolol
vs
metoprolol succinate
cIBIS-II (N=2647; 95% cI,19-46; P<.0001; NNT=23)
vs
mErIT-hF (N=2002; 95% cI, 24-56; P<.0001; NNT=16)
34%
vs
42%
carvedilol 
vs
metoprolol succinate
coPErNIcuS (N=2289; 95% cI,19-48; P=.0014; NNT=14)
vs
mErIT-hF (N=795; 95% cI, 11-58; P=.0086; NNT=14)
35%
vs
39%
Nebivolol
vs
metoprolol succinate
SENIorS-ShF (N=1359; NS; NNT=63) 
vs
mErIT-hF  (N=985; 95% cI, 2-53; P=.038; NNT=21)
16%
vs
32%
cI, confidence interval; EF, ejection fraction; cIBIS-II, cardiac Insufficiency Bisoprolol Study II (EF<35%); coPErNIcuS, carve-
dilol Prospective randomized cumulative Survival trial (EF<25%); mErIT-hF, metoprolol cr/Xl randomized Intervention 
Trial in congestive heart Failure (EF<40%); NNT, number needed to treat; NS, not significant; rrr, relative risk reduction; 
SENIorS-ShF, Study of the Effects of Nebivolol Intervention on outcomes and rehospitalization in Seniors with heart 
Failure trial.
* relative risk reduction of annual mortality rates from placebo to beta-blocker arms.
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